Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 16/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 15/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 10/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 10/20 | 1.00 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 1.00 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 1.00 |
| ▸ | PIK3C2A | O00443 | 1/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 1/20 | 1.00 |
| ▸ | PI4KA | P42356 | 1/20 | 1.00 |
| ▸ | PRKDC | P78527 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373332 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL29180139 | 0.87 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL14851735 | 0.87 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL48677 | 0.86 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL21096715 | 0.86 | PIK3CD (0.75) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL14385624 | 0.85 | PIK3CD (0.73) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL48485 | 0.84 | PIK3CD (0.72) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL48392 | 0.84 | PIK3CG (0.83) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL14851611 | 0.84 | PIK3CG (0.72) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL14851723 | 0.84 | PIK3CD (0.72) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| US-20190070166-A1 | Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease | POSTREL RICHARD (US) | 2019-03-07 | — | — | US | claimed |
| US-9301961-B2 | Autoimmune and inflammatory disorder therapy | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2016-04-05 | — | — | US | claimed |
| US-20140294870-A1 | Autoimmune and Inflammatory Disorder Therapy | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2014-10-02 | — | — | US | claimed |
| WO-2014083327-A1 | ADENINE DERIVATIVES SUITABLE FOR THE TREATMENT OF (INTER ALIA) MUSCULAR DYSTROPHY | MD PHARMA AB (SE) | 2014-06-05 | — | — | WO | claimed |
| EP-1480962-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | claimed |
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220031853-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2022-02-03 | — | — | US | disclosed |
| US-20220017905-A1 | METHODS FOR IDENTIFYING THERAPEUTIC TARGETS AND TREATING AND MONITORING CANCERS | FRED HUTCHINSON CANCER CENTER | 2022-01-20 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| US-20210000966-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2021-01-07 | — | — | US | disclosed |
| US-10676746-B2 | Methods for identifying therapeutic targets and treating monitoring cancers | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2020-06-09 | — | — | US | disclosed |
| WO-2012118978-A1 | METHODS FOR TREATING ONCOVIRUS POSITIVE CANCERS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2012-09-07 | — | — | WO | disclosed |
| US-8129541-B2 | 5-phenylthiazole derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-1480962-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| EP-2311818-A1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | Novartis AG (CH) | 2011-04-20 | — | — | EP | disclosed |
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | BRUCE IAN | 2010-04-15 | — | — | US | disclosed |
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | NOVARTIS AG (CH) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | PIK3CA, PIK3R5, PIP5K1B | PIK3CD 4/4885PIK3CG 8/4885PIK3CA 1/4885 |
| US-20210000966-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90AA1, HSP90B1 | PIK3CD 3905/4885PIK3CG 3503/4885PIK3CA 3406/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | PIK3CD 1353/4885PIK3CG 1894/4885PIK3CA 426/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | PIK3CD 2515/4885PIK3CG 3107/4885PIK3CA 1228/4885 |
| US-20140294870-A1 | Autoimmune and Inflammatory Disorder Therapy | PI4KB, PI4KA, PI4K2B | PIK3CD 10/4885PIK3CG 18/4885PIK3CA 30/4885 |
| US-20220031853-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90AA1, HSP90B1 | PIK3CD 3905/4885PIK3CG 3503/4885PIK3CA 3406/4885 |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | PIK3CA, PIK3R5, PIP5K1B | PIK3CD 4/4885PIK3CG 8/4885PIK3CA 1/4885 |
| US-20220017905-A1 | METHODS FOR IDENTIFYING THERAPEUTIC TARGETS AND TREATING AND MONITORING CANCERS | TP53, KRAS, VHL | PIK3CD 1072/4885PIK3CG 988/4885PIK3CA 166/4885 |
| US-10676746-B2 | Methods for identifying therapeutic targets and treating monitoring cancers | TP53, KRAS, MYC | PIK3CD 910/4885PIK3CG 916/4885PIK3CA 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.